Hyundai Bioscience Co., Ltd. (048410.KQ)
KRW 10770.0
(0.19%)
KRW 10770.0
(0.19%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -365.00 KRW | 9.21% |
| 2022 | -401.53 KRW | 26.08% |
| 2021 | -543.16 KRW | -136.17% |
| 2020 | -229.99 KRW | -1138.33% |
| 2019 | 22.15 KRW | -71.47% |
| 2018 | 77.64 KRW | 107.59% |
| 2017 | 37.40 KRW | 114.04% |
| 2016 | -266.38 KRW | -1234.5% |
| 2015 | 23.48 KRW | 152.53% |
| 2014 | -44.70 KRW | 89.36% |
| 2013 | -420.25 KRW | -0.28% |
| 2012 | -419.06 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 29.77 KRW | 114.66% |
| 2024 Q2 | 57.94 KRW | 94.63% |
| 2023 Q3 | -49.72 KRW | 15.34% |
| 2023 Q1 | -52.82 KRW | 81.68% |
| 2023 FY | - KRW | 9.21% |
| 2023 Q4 | -203.13 KRW | -308.55% |
| 2023 Q2 | -58.73 KRW | -11.19% |
| 2022 FY | - KRW | 26.08% |
| 2022 Q4 | -288.33 KRW | -440.33% |
| 2022 Q1 | -55.11 KRW | 84.23% |
| 2022 Q2 | -149.15 KRW | -170.64% |
| 2022 Q3 | 84.72 KRW | 156.8% |
| 2021 Q1 | -55.72 KRW | 69.58% |
| 2021 Q4 | -349.56 KRW | -394.5% |
| 2021 FY | - KRW | -136.17% |
| 2021 Q2 | -53.19 KRW | 4.54% |
| 2021 Q3 | -70.69 KRW | -32.9% |
| 2020 Q1 | -33.00 KRW | -13100.0% |
| 2020 Q3 | -9.00 KRW | -78.57% |
| 2020 Q4 | -183.15 KRW | -1935.0% |
| 2020 FY | - KRW | -1138.33% |
| 2020 Q2 | -5.04 KRW | 84.73% |
| 2019 Q4 | -0.25 KRW | -101.05% |
| 2019 Q3 | 23.72 KRW | 174.86% |
| 2019 Q2 | 8.63 KRW | -35.93% |
| 2019 Q1 | 13.47 KRW | -76.66% |
| 2019 FY | - KRW | -71.47% |
| 2018 FY | - KRW | 107.59% |
| 2018 Q3 | 24.19 KRW | 492.89% |
| 2018 Q2 | 4.08 KRW | 143.17% |
| 2018 Q1 | -9.45 KRW | -118.04% |
| 2018 Q4 | 57.71 KRW | 138.57% |
| 2017 Q3 | 19.00 KRW | 869.39% |
| 2017 FY | - KRW | 114.04% |
| 2017 Q2 | 1.96 KRW | 105.19% |
| 2017 Q1 | -37.78 KRW | 80.35% |
| 2017 Q4 | 52.39 KRW | 175.74% |
| 2016 Q3 | -70.00 KRW | -657.58% |
| 2016 Q4 | -192.25 KRW | -174.64% |
| 2016 FY | - KRW | -1234.5% |
| 2016 Q1 | 4.63 KRW | 121.82% |
| 2016 Q2 | -9.24 KRW | -299.57% |
| 2015 Q3 | 31.00 KRW | 209.38% |
| 2015 Q1 | 5.21 KRW | 193.2% |
| 2015 FY | - KRW | 152.53% |
| 2015 Q4 | -21.22 KRW | -168.45% |
| 2015 Q2 | 10.02 KRW | 92.32% |
| 2014 Q3 | 6.22 KRW | 121.17% |
| 2014 Q1 | -18.31 KRW | 93.27% |
| 2014 FY | - KRW | 89.36% |
| 2014 Q4 | -5.59 KRW | -189.87% |
| 2014 Q2 | -29.38 KRW | -60.46% |
| 2013 Q2 | -126.00 KRW | -66.29% |
| 2013 Q4 | -272.25 KRW | -479.26% |
| 2013 Q3 | -47.00 KRW | 62.7% |
| 2013 FY | - KRW | -0.28% |
| 2013 Q1 | -75.77 KRW | -275.1% |
| 2012 Q4 | -20.20 KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | -463.03 KRW | 21.171% |
| ST Pharm Co.,Ltd. | 1041.07 KRW | 135.06% |
| ABL Bio Inc. | -55.32 KRW | -559.798% |
| Cellid, Co., Ltd. | -1078.05 KRW | 66.143% |